Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Usana Health Sciences (USNA) Other Non Operating Income (2016 - 2026)

Usana Health Sciences has reported Other Non Operating Income over the past 17 years, most recently at $1.4 million for Q2 2026.

  • Quarterly Other Non Operating Income rose 84.39% to $1.4 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Apr 2026, up 4679.71% year-over-year, with the annual reading at $2.5 million for FY2026, 349.46% up from the prior year.
  • Other Non Operating Income was $1.4 million for Q2 2026 at Usana Health Sciences, up from -$14000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $1.7 million in Q2 2025 and troughed at -$1.2 million in Q1 2022.
  • The 5-year median for Other Non Operating Income is -$137000.0 (2023), against an average of -$49222.2.
  • Year-over-year, Other Non Operating Income tumbled 769.86% in 2022 and then surged 598.28% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at -$1.2 million in 2022, then surged by 68.71% to -$368000.0 in 2023, then fell by 5.98% to -$390000.0 in 2024, then soared by 110.51% to $41000.0 in 2025, then surged by 3300.0% to $1.4 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's Other Non Operating Income are $1.4 million (Q2 2026), -$14000.0 (Q1 2026), and $41000.0 (Q3 2025).